硝苯地平与阿托西班对围产期脑损伤的影响:APOSTEL-III试验的二次分析
该研究为APOSTEL-III随机临床试验的二次分析,纳入两个主要中心孕25至34周先兆早产并接受硝苯地平或阿托西班治疗、且分娩孕周≤32周的117例新生儿。结果显示硝苯地平组总体脑损伤发生率为43.1%,阿托西班组为56.1%(OR 0.60,95%CI 0.29-1.24),轻度和重度脑损伤组间均无显著差异。作者结论为早产儿脑损伤患病率高,两种宫缩抑制剂组间无显著差异,但该二次分析对脑损伤的检验效能不足。
要点
- 硝苯地平组总体脑损伤43.1%,阿托西班组56.1%,OR 0.60(95%CI 0.29-1.24),组间无显著差异。
- 脑室出血(≥I级)是最常见的超声异常,硝苯地平组35.3% vs 阿托西班组37.9%(OR 0.90,95%CI 0.42-1.91)。
- 重度脑损伤硝苯地平组9.8% vs 阿托西班组7.6%(OR 1.33,95%CI 0.36-4.85)。
核心结论
- 孕32周前早产儿中脑损伤患病率高,硝苯地平暴露与阿托西班暴露新生儿之间总体脑损伤无显著差异。
- 该研究为APOSTEL-III试验的二次分析,对脑损伤的检验效能不足。
研究设计与样本
- 研究类型为随机临床试验(APOSTEL-III,荷兰临床试验注册号NTR2947)的二次分析。
- 纳入孕25至34周先兆早产并接受硝苯地平或阿托西班治疗、且分娩孕周≤32周的新生儿,来自两个主要贡献中心。
- 共纳入117例新生儿(来自102例孕妇),其中硝苯地平组51例,阿托西班组66例。
- 主要结局为新生儿脑损伤,定义为超声检查存在异常,并分为轻度和重度;分析新生儿重症及中级监护期间所有超声检查。
- 进行敏感性分析,调整母亲年龄和随机化时孕周,评估基线或已知脑损伤危险因素的差异。
关键影像表现/征象
- 脑室出血(≥I级)是最常见的超声异常,硝苯地平组18例(35.3%)vs 阿托西班组25例(37.9%)(OR 0.90,95%CI 0.42-1.91)。
诊断标准与关键数值
- 脑损伤定义为超声检查存在异常,并分类为轻度与重度。
- 总体脑损伤:硝苯地平组22例(43.1%)vs 阿托西班组37例(56.1%)(OR 0.60,95%CI 0.29-1.24)。
- 轻度脑损伤:硝苯地平组33.3% vs 阿托西班组48.5%(OR 0.53,95%CI 0.25-1.13)。
- 重度脑损伤:硝苯地平组9.8% vs 阿托西班组7.6%(OR 1.33,95%CI 0.36-4.85)。
- 敏感性分析调整母亲年龄和随机化时孕周后,组间脑损伤存在与否无统计学差异(OR 0.58,95%CI 0.27-1.27)。
临床应用与阅片要点
- 在判读早产儿颅脑超声时,脑室出血(≥I级)为最常见异常,需按轻度与重度分类报告。
- 本文为二次分析且对脑损伤检验效能不足,组间无显著差异的结果不能解读为两种宫缩抑制剂对脑损伤有等效性。
局限性
- 该研究为APOSTEL-III试验的二次分析,对脑损伤的检验效能不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Brain injury in neonates born prematurely is associated strongly with poor neurodevelopmental outcome. The aim of this study was to evaluate whether tocolysis with nifedipine or atosiban in women with threatened preterm birth can reduce the incidence of overall brain injury in neonates born prematurely.
METHODS: This was a secondary analysis of the APOSTEL-III trial (Dutch Clinical Trial Registry, no. NTR2947), a randomized clinical trial in which women with threatened preterm labor between 25 and 34 weeks of gestation were allocated to treatment with nifedipine or atosiban. In this secondary analysis, women delivered at ≤ 32 weeks of gestational age in the two main contributing centers were included. Primary outcome was the presence of neonatal brain injury, which was defined as presence of abnormalities on ultrasound investigation and classified into mild and severe. To evaluate type and severity of brain injury, all neonatal ultrasounds performed during neonatal intensive and medium care admission were analyzed. To test the robustness of our results, a sensitivity analysis was performed assessing differences in baseline or known risk factors for brain injury.
RESULTS: A total of 117 neonates (from 102 women) were studied, of which 51 had been exposed to nifedipine and 66 to atosiban. Brain injury was observed in 22 (43.1%) neonates in the nifedipine group compared with 37 (56.1%) in the atosiban group (OR, 0.60; 95% CI, 0.29-1.24). Presence of mild brain injury was comparable between the nifedipine (33.3%) and atosiban (48.5%) groups (OR, 0.53; 95% CI, 0.25-1.13). Severe brain injury was also comparable between the groups, observed in 9.8% of neonates in the nifedipine vs 7.6% of those in the atosiban group (OR, 1.33; 95% CI, 0.36-4.85). Intraventricular hemorrhage (≥ Grade I) was the most frequently seen ultrasound abnormality, observed in 18 (35.3%) neonates in the nifedipine group vs 25 (37.9%) in the atosiban group (OR, 0.90; 95% CI, 0.42-1.91). The sensitivity analysis, with adjustment for maternal age and gestational age at randomization, showed no statistical difference between the groups for presence of brain injury (OR, 0.58; 95% CI, 0.27-1.27).
CONCLUSION: In children born before 32 weeks of gestation after the use of tocolytics, the prevalence of brain injury was high. No significant differences were found with respect to overall brain injury between neonates exposed to nifedipine and those exposed to atosiban. However, as this study was a secondary analysis of the APOSTEL III trial, it was underpowered for brain injury. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Nijman TAJ, Goedhart MM, Naaktgeboren CN, et al. Effect of nifedipine and atosiban on perinatal brain injury: secondary analysis of the APOSTEL-III trial. Ultrasound Obstet Gynecol. 2018. PMID: 28452086. doi:10.1002/uog.17512
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。